Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. - Test2 - elhamkhani - TriplyDB

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

http://www.wikidata.org/entity/Q40298570

about

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 Self-association of human PCSK9 correlates with its LDLR-degrading activity Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain Molecular biology of PCSK9: its role in LDL metabolism The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.Autosomal dominant hypercholesterolemia: needs for early diagnosis and cascade screening in the tunisian population.The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers.The genetic spectrum of familial hypercholesterolemia in Pakistan Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells.Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.A new method for measurement of total plasma PCSK9: clinical applications.Selection of DNA aptamers with two modified bases.Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.Anti-PCSK9 therapies for the treatment of hypercholesterolemia.Genetics of coronary artery disease and myocardial infarction--2013.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Insights from human congenital disorders of intestinal lipid metabolism.Shared genetic aetiology of coronary artery disease and atherosclerotic stroke - 2015.Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.PCSK9 function and physiology

P2860

Q21136366-ED83CF9D-E7BF-4BEC-A4CF-1FF70EB875D1 Q24298534-91A21203-0A94-48E1-A684-6115A5CF4856 Q24299848-8734C258-8856-4F59-B27A-CDD203FE6892 Q24301411-6CA89801-21F1-430E-A186-031F78826136 Q24306591-977A1941-147A-4348-847C-BF68010CA80B Q24311328-865C0C43-3A6E-47D2-A15B-88CC2C598921 Q24313575-F3A46E14-8AAC-4116-8487-B91A1C9BCC57 Q27339783-52396A00-5C4D-4630-8B7D-FFF03008264F Q27488922-98636DA1-3B3C-4896-BD50-9A8139E4D659 Q27647905-ADA29D3D-A5EB-4E0F-8211-D9FE8DBA76C4 Q27653836-072D2DE7-97B1-44C5-ADA3-862535F700ED Q28292154-F10D4A99-BF77-42A3-A42B-20AFE7989DB9 Q28304381-FA374388-3724-42F6-853E-BC6B2EE1E2C4 Q34227474-847D002F-45CC-4B38-B364-E91BB2265C94 Q34430377-CA02E003-831A-4FF3-9936-D79D8A28E037 Q34634698-84234076-13BA-43D4-BC28-497DAA090E63 Q34951227-660E72CB-FE2A-4B5D-AC7F-D920CCB455FB Q35015811-EC65B271-B50F-47F7-8B76-D978288ACB6A Q35767551-94F42050-0EA8-44FA-A7D9-5CB51D6528CB Q35847854-0AFE39AA-B29D-46F6-A635-9893FA12831E Q36506609-5677BF22-35A8-42B1-9E93-141FC3984FF7 Q36520347-50FF3728-E776-448A-9C0D-8ADE86E1FE2E Q36634114-28FB0745-6F14-41B6-A75A-EC8EEB78E06F Q36925157-05E0D22F-591D-413B-8872-D2387F05934F Q36942847-70675F7E-5B6C-44E7-9844-B1B35365AFA2 Q36983501-11C9210E-AE0E-4118-A673-C70C23440585 Q37101312-6A6B2E74-2AFC-4464-B2A4-E5B6B2A6104D Q37297854-9885A848-A342-4729-84CA-754C7F3B352D Q37384902-73AB722A-BFFA-4F33-ABF2-1496DEE31BFA Q37463260-2F977F12-5AD0-4C05-AD75-A9E4FA7A7E77 Q37711632-6DFF7A67-F6CF-49B1-8633-965DA43DE106 Q37789741-FA930DA5-267D-4185-A277-93F419556772 Q37825903-0B2A1E49-331E-4405-8DB5-4D8F86DE887C Q38067460-A487CD39-2A14-4D2B-B528-D0C859188DA7 Q38101513-82EF5A99-E1C4-41F3-BBB0-BE51E65FC2D8 Q38109960-0153E485-DF3D-4763-A748-7DE8C7482417 Q38267212-5DD256A7-8F81-4D9C-8838-F55A984BE4F8 Q38359111-3B63190C-6452-4BE2-9826-B563F44577AE Q38415736-1545174E-5322-413B-B7BC-97E092F7A199 Q38531200-95F38F00-F53C-4F89-B2E2-F0AACC1359F8

P2860

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

http://www.wikidata.org/entity/Q40298570

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

@en

type

label

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

@en

prefLabel

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

@en

P1433

Q40298570-2923599D-E23F-4F07-B66F-7BF793739872

P1476

Q40298570-B79F8A98-BF2B-44B6-BD9A-DFA8F2BD560F

P2093

Q40298570-1DE19A20-DAC1-4426-85D1-34DF04544CEC

Q40298570-4489CA4D-FF55-4EAC-9BD1-2D4BBADB1875

Q40298570-5FB830EF-10F1-42FC-AB85-F9EA6A3AA6FC

Q40298570-C8A82EAA-2A2C-4D40-BD55-DC903E63D9CE

Q40298570-CA0BC031-5146-45D2-8F6B-855328B08025

Q40298570-EBB1B920-71E1-4BDD-BA23-4686789E611F

P2860

Q40298570-3F7D996B-1A6E-45EF-B14E-A501F345B619

Q40298570-40ACFB83-B5A6-4398-AEAC-FF0D770E500E

Q40298570-4A18D195-8ABD-4FD2-91EA-562BD0B3B10D

Q40298570-58C04F7E-F71D-4221-99D4-76AA53EE4C0E

Q40298570-5C635079-A4DE-419B-B61C-6B9ED7BC54D7

Q40298570-634D377B-8090-47ED-9F57-9005ED4DF9D6

Q40298570-678E5707-F63A-4ED9-BC65-CF1876E7CD8D

Q40298570-7BBD8F7A-24C1-44C2-B8E2-252E22C437BC

P304

Q40298570-8D843C98-D3E0-48A2-B0E8-990397DAC49C

P31

Q40298570-CEB7F419-37B7-452E-83A5-06D759925AF6

P356

Q40298570-496A1006-B236-4223-AB97-65098141FFAA

P433

Q40298570-450EED26-DD9C-408E-AFE1-7263F8A1AA3E

P478

Q40298570-4B64F6FB-534B-431D-8D1E-E37A7248F262

P577

Q40298570-190FAA80-B7F5-40CD-B9B2-3161028285A2

P5875

Q40298570-762CB55A-5647-4B57-8D0D-D6A2A7615F48

P698

Q40298570-BF02C2DA-AB14-4FC9-AC31-6F4D2358A858

P356

P1433

Human Molecular Genetics

P1476

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

@en

P2093

Jamie Cameron

http://www.w3.org/2001/XMLSchema#string

Knut Erik Berge

http://www.w3.org/2001/XMLSchema#string

Mari Ann Kulseth

http://www.w3.org/2001/XMLSchema#string

Trine Ranheim

http://www.w3.org/2001/XMLSchema#string

Trond P Leren

http://www.w3.org/2001/XMLSchema#string

Øystein L Holla

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

P304

1551-1558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDL077

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7207036

http://www.w3.org/2001/XMLSchema#string

P698

16571601

http://www.w3.org/2001/XMLSchema#string